Directing the Metabolism of Drugs Away from CYP450: The Use of Oxetane Rings
Open Access
- 1 January 2019
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Pharmacology & Pharmacy
- Vol. 10 (11), 465-473
- https://doi.org/10.4236/pp.2019.1011038
Abstract
Treatment of health problems that accompany aging often includes pharmacotherapy. It is thus common for older adults—and, increasingly, younger adults—to be on multiple medications, either prescription or over-the-counter (OTC). With the consumption of multiple medications, drug-drug interactions (DDIs) are a concern. The site of drug-drug interactions is often at the level of drug metabolism. If a drug inhibits (or enhances) the metabolism of another, the blood level (therapeutic effect) can be decreased below the required level, or adverse effects can increase. Because most currently used drugs are metabolized via cytochrome P450-catalyzed pathways, drug discovers seek drugs that are metabolized by alternate pathways. Medicinal chemists have come upon a strategy—the incorporation of oxetane rings in the drug structure—that increases the likelihood that a drug will not be metabolized via CYP450. The same modification gives other desirable physical properties to the molecule. Although there are no guarantees that there will be fewer DDIs or an absence of other unexpected problems, the strategy could pave the way for new drugs that are safer and easier to use with concomitant medications.Keywords
This publication has 34 references indexed in Scilit:
- Understanding and Meeting the Needs of the Older Population: A Global ChallengeCanadian Geriatrics Journal, 2013
- Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase InhibitorsJournal of Medicinal Chemistry, 2011
- Oxetanes in Drug Discovery: Structural and Synthetic InsightsJournal of Medicinal Chemistry, 2010
- Aging Biology and Geriatric Clinical PharmacologyPharmacological Reviews, 2004
- Effects of C2-Alkylation, N-Alkylation, and N,N‘-Dialkylation on the Stability and Estrogen Receptor Interaction of (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolinesJournal of Medicinal Chemistry, 2004
- A PASSION FOR P450s (REMEMBRANCES OF THE EARLY HISTORY OF RESEARCH ON CYTOCHROME P450)Drug Metabolism and Disposition, 2003
- Design and Synthesis of Pyrrolidine-5,5‘-trans-Lactams (5-Oxo-hexahydropyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 4. Antiviral Activity and Plasma StabilityJournal of Medicinal Chemistry, 2003
- Drugs and the liver. Part III: Ageing of the liver and the metabolism of drugsBiopharmaceutics & Drug Disposition, 1992
- Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseasesJournal of Medicinal Chemistry, 1987
- Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase SystemsScience, 1965